First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
8/14/26
TG THERAPEUTICS (TGTX)
Friday
9:42 AM
Thesis: TG Therapeutics: the setup is constructive — Briumvi quarterly prescription trends (TRx and NBRx data from IQVIA) and market share gains in relapsing MS segment
growth - Attracts growth investors focused on commercial-stage biotech with single-product revenue inflection.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for growth…
Watch on earnings: Briumvi weekly prescription data (NBRx and TRx) from Symphony Health or IQVIA, Quarterly net product revenue and gross-to-net percentage (rebates, discounts, co-pay assistance), Operating cash flow trajectory and quarters to sustained positive OCF.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $956M to $1.3B as briumvi quarterly prescription trends (trx and nbrx data from iqvia) and market share gains in relapsing ms segment.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.